

Katerina Pavenski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/813624/publications.pdf>

Version: 2024-02-01

64
papers

2,302
citations

471371

17
h-index

223716

46
g-index

69
all docs

69
docs citations

69
times ranked

2823
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement-Amplifying Conditions in Atypical Hemolytic Uremic Syndrome: A Canadian Case Series. Canadian Journal of Kidney Health and Disease, 2022, 9, 205435812211002.	0.6	0
2	TACO&BELL&E3: a feasibility study and a retrospective audit of diuretics for patients receiving blood transfusion at ten hospitals. Vox Sanguinis, 2021, 116, 434-439.	0.7	3
3	Infants affected by Rh sensitization: A 2-year Canadian National Surveillance Study. Paediatrics and Child Health, 2021, 26, 159-165.	0.3	0
4	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances, 2021, 5, 2137-2141.	2.5	39
5	Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021, 137, 1855-1861.	0.6	103
6	Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine. TH Open, 2021, 05, e335-e337.	0.7	13
7	Blood"brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study. Blood Advances, 2021, 5, 4211-4218.	2.5	4
8	A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin—mediated hemolysis. Transfusion, 2021, 61, 1053-1063.	0.8	15
9	Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110087.	0.6	18
10	The clock is ticking: using in situ simulation to improve time to blood administration for bleeding trauma patients. Canadian Journal of Emergency Medicine, 2021, 23, 54-62.	0.5	6
11	Sex Differences in Anemia and Red Blood Cell Transfusions Among General Internal Medicine Inpatients. Blood, 2021, 138, 1074-1074.	0.6	0
12	Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study. Blood, 2021, 138, 2080-2080.	0.6	0
13	Efficacy and safety of open&label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of Thrombosis and Haemostasis, 2020, 18, 479-484.	1.9	45
14	In reply: Erythropoietin and iron: separating the builder from his blocks. Canadian Journal of Anaesthesia, 2020, 67, 388-389.	0.7	0
15	Describing the point prevalence and characteristics of venous thromboembolism in patients with thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2870-2877.	1.9	7
16	When to transfuse your acute care patient? A narrative review of the risk of anemia and red blood cell transfusion based on clinical trial outcomes. Canadian Journal of Anaesthesia, 2020, 67, 1576-1594.	0.7	9
17	Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness. Transfusion Medicine Reviews, 2020, 34, 250-257.	0.9	26
18	The utility of a monocyte monolayer assay in the assessment of <scpi>intravenous immunoglobulin</scpi>"associated hemolysis. Transfusion, 2020, 60, 3010-3018.	0.8	6

#	ARTICLE	IF	CITATIONS
19	The First North American Experience Using Glycosorb Immunoabsorption Columns for Blood Groupâ€“Incompatible Kidney Transplantation. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096258.	0.6	3
20	New mutation found to cause hereditary thrombotic thrombocytopenic purpura in a patient presenting with seizures in adulthood. <i>Platelets</i> , 2020, 31, 1094-1096.	1.1	1
21	Evaluation of ethnicity as a predictor of diagnostic phenotype and prognosis in neuromyelitis optica spectrum disorder in Toronto, Canada. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101950.	0.9	9
22	Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435811989722.	0.6	5
23	Bendamustine-induced immune hemolytic anemia: a case report and systematic review of the literature. <i>Blood Advances</i> , 2020, 4, 1756-1759.	2.5	12
24	Urgent Transfusion in a New Patient with Rare Blood Type. <i>Blood</i> , 2020, 136, 28-28.	0.6	0
25	Development and implementation of a quality improvement toolkit, iron deficiency in pregnancy with maternal iron optimization (IRON MOM): A before-and-after study. <i>PLoS Medicine</i> , 2019, 16, e1002867.	3.9	10
26	Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1966.	3.8	106
27	A curious case of delayed hemolytic transfusion reaction with evanescent antibodies in a patient with hereditary hemorrhagic telangiectasia. <i>Transfusion</i> , 2019, 59, 3570-3574.	0.8	0
28	A regional massive hemorrhage protocol developed through a modified Delphi technique. <i>CMAJ Open</i> , 2019, 7, E546-E561.	1.1	17
29	Appropriateness of intravenous immunoglobulin use in immune thrombocytopenia (ITP): A Canadian centre deep dive audit. <i>Transfusion and Apheresis Science</i> , 2019, 58, 491-494.	0.5	4
30	Patient Blood Management. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 983.	3.8	419
31	Transfusion Camp: a prospective evaluation of a transfusion education program for multispecialty postgraduate trainees. <i>Transfusion</i> , 2019, 59, 2141-2149.	0.8	20
32	Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis. <i>Canadian Journal of Anaesthesia</i> , 2019, 66, 716-731.	0.7	71
33	A case for consideration by apheresis practitioners: Melanoma and PD-1 inhibitor treatment in a patient with multiple relapses of immune thrombotic thrombocytopenic purpura. <i>Transfusion and Apheresis Science</i> , 2019, 58, 123-124.	0.5	3
34	Massive hemorrhage protocol survey: Marked variability and absent in one-third of hospitals in Ontario, Canada. <i>Injury</i> , 2019, 50, 46-53.	0.7	13
35	Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , 2019, 380, 335-346.	13.9	625
36	A rationale for universal tranexamic acid in major joint arthroplasty: overall efficacy and impact of risk factors for transfusion. <i>Transfusion</i> , 2019, 59, 207-216.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2019, 134, 2381-2381.	0.6	0
38	ABO zygosity, but not secretor or Fc receptor status, is a significant risk factor for IVIG-associated hemolysis. <i>Blood</i> , 2018, 131, 830-835.	0.6	19
39	Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2018, 132, 373-373.	0.6	2
40	Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2018, 132, 3739-3739.	0.6	3
41	Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study. <i>Blood</i> , 2018, 132, 3744-3744.	0.6	3
42	Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study. <i>Blood</i> , 2018, 132, 1142-1142.	0.6	3
43	Adamts-13 Inhibitor Testing Is Often Negative on Initial Testing. <i>Blood</i> , 2018, 132, 5051-5051.	0.6	1
44	Multi-Center Evaluation of the Automated Immunohematology Instrument, the ORTHO VISION Analyzer. <i>Laboratory Medicine</i> , 2017, 48, 29-38.	0.8	4
45	How we treat thrombotic thrombocytopenic purpura: Results of a Canadian TTP practice survey. <i>Journal of Clinical Apheresis</i> , 2017, 32, 246-256.	0.7	15
46	Risks of novel therapeutics: gonococemia in an immune-suppressed patient receiving eculizumab. <i>Cmaj</i> , 2017, 189, E1558-E1560.	0.9	12
47	Evaluating appropriate red blood cell transfusions: a quality audit at 10 Ontario hospitals to determine the optimal measure for assessing appropriateness. <i>Transfusion</i> , 2016, 56, 2466-2476.	0.8	25
48	Thrombocytopenia and Microangiopathic Hemolytic Anemia Precipitated By Acute Pancreatitis: A Single Center Experience of Five Cases. <i>Blood</i> , 2016, 128, 1377-1377.	0.6	2
49	Bleeding complications from the direct oral anticoagulants. <i>BMC Hematology</i> , 2015, 15, 18.	2.6	8
50	Western immunoblotting as a new tool for investigating direct antiglobulin testâ€“negative autoimmune hemolytic anemias. <i>Transfusion</i> , 2015, 55, 1529-1537.	0.8	6
51	Guidance on Platelet Transfusion for Patients With Hypoproliferative Thrombocytopenia. <i>Transfusion Medicine Reviews</i> , 2015, 29, 3-13.	0.9	87
52	Severe Delayed Hemolysis Associated with Regulated Parenteral Antimalarial Drug. <i>Emerging Infectious Diseases</i> , 2015, 21, 164-166.	2.0	11
53	Weak D type 67 in four related Canadian blood donors. <i>Immunohematology</i> , 2015, 31, 159-62.	0.2	0
54	Blood Conservation in Neurosurgery: Erythropoietin and Autologous Donation. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 583-589.	0.3	18

#	ARTICLE	IF	CITATIONS
55	PBM symposium introduction. <i>Transfusion and Apheresis Science</i> , 2014, 50, 3-4.	0.5	1
56	Comparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 431-442.	3.0	98
57	Utility of Complement and ADAMTS13 Testing in Diagnosis of Thrombotic Microangiopathy: A Single Centre Retrospective Review. <i>Blood</i> , 2014, 124, 2787-2787.	0.6	0
58	Genotype Phenotype Correlation in Patients with aHUS and Abnormal Genetic Studies: A Single Centre Experience. <i>Blood</i> , 2014, 124, 4186-4186.	0.6	0
59	Plasmapheresis and Steroid Treatment of Levamisole-Induced Vasculopathy and Associated Skin Necrosis in Crack/Cocaine Users. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 123-128.	0.6	23
60	Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. <i>Transfusion</i> , 2013, 53, 2230-2242.	0.8	40
61	HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. <i>Tissue Antigens</i> , 2012, 79, 237-245.	1.0	130
62	Erythropoietic neuroprotection: Holy Grail or potential to fail?. <i>Intensive Care Medicine</i> , 2011, 37, 1403-1405.	3.9	1
63	Is thrombotic microangiopathy a paraneoplastic phenomenon? Case report and review of the literature. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 292-294.	1.4	1
64	HIV-Associated Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2011, 118, 4677-4677.	0.6	3